Shadowfax Technologies is opening its Initial Public Offering (IPO) today on January 20, 2026. The public subscription window will be open from January 20 till January 22, 2026. The allotment process for Shadowfax IPO is expected to be finalised on January 23, 2026 and the shares will be listed on both the NSE and BSE. The tentaive listing date is fixed as January 28, 2026.
Shadowfax Technologies is a third-party logistics company focused on facilitating digital commerce in India. Its services include express forward parcel deliveries, reverse pickups, exchange deliveries, prime deliveries, quick commerce and hyperlocal deliveries, mobility services, and critical logistics solutions.
[January 20, 2026, 10:45 AM]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
- |
|
Non-Institutional Investors |
0.05 |
|
Retail Individual Investors (RIIs) |
0.38 |
|
Employees |
0.28 |
|
Total |
0.08 |
Explore other Upcoming IPOs on BSE and NSE.
The net proceeds from the fresh issue will be used towards the following purposes:
Check out newly Listed IPOs on BSE and NSE.
As per media reports, the Grey Market Premium (GMP) of Shadowfax Technologies Ltd is reported at ₹6 or 4.84% over the upper end of the price band.
Shadowfax Technologies Ltd is a Bengaluru-based, technology-led third-party logistics (3PL) and delivery services company, founded in 2015 by Abhishek Bansal and Vaibhav Khandelwal. It operates an extensive logistics network across India, providing end-to-end express parcel delivery, reverse logistics, same-day and next-day services, quick commerce and other value-added logistics solutions to e-commerce, quick commerce, D2C brands and on-demand platforms.
Financially, the company has shown rapid growth in recent years. For the year ended March 31, 2025 (FY25), Shadowfax reported revenue of approximately ₹2,515 crore, up from about ₹1,896 crore in FY24.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here